Dr Reddy's launches Aspirin and Dipyridamole capsules in US market
Quoting IMS Health data, Dr Reddy's Laboratories said the Aggrenox brand and generic had US sales of approximately USD 182 million for the most recent 12 months ending in October 2018.
New Delhi: Drug major Dr Reddy's Laboratories Monday announced the launch of anti-coagulant drug Aspirin and extended-release dipyridamole capsules in the US market. The product is a therapeutic equivalent to the generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company said in a BSE filing.
Quoting IMS Health data, Dr Reddy's Laboratories said the Aggrenox brand and generic had US sales of approximately USD 182 million for the most recent 12 months ending in October 2018.
Read Also: Dr Reddy’s Lab launches Omeprazole in the US market
Dr Reddy's Aspirin and extended-release Dipyridamole capsules are available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer Ingelheim.
The stock of Dr Reddy's Laboratories was trading 0.48 per cent lower at Rs 2,591.45 apiece on BSE.
Read Also: Dr Reddy’s Labs launches Atomoxetine Capsules in US Market
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd